<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611819</url>
  </required_header>
  <id_info>
    <org_study_id>KHRONOS</org_study_id>
    <secondary_id>2005-000203-34</secondary_id>
    <nct_id>NCT00611819</nct_id>
  </id_info>
  <brief_title>Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV</brief_title>
  <official_title>Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rapidly progression of the disease in HIV-HCV co-infected patients justify the treatment.

      Combination of Peg interferon and Ribavirin is the best treatment because it improve the
      compliance of treatment.

      In APRICOT study genotypes 2 and 3 patients received 48 weeks and the rates of end of
      treatment response was 64% and the sustained virological response (24 weeks after the end of
      treatment) 62%.

      In mono-infected patients trials showed there are not differences in the sustained
      virological response between 24 and 48 weeks of treatment, however exit the doubt concerning
      the different kinetic viral in HIV-HCV co-infected patients and this could be related with a
      lost of profit with a shorter duration of treatment, only 24 weeks.

      In this study we woud like to evaluate if 24 weeks of treatment in HIV-HCV co-infected
      patients genotype 2 or 3 will have the same rate of clearance of virus at the end of
      follow-up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will randomized to receive 180 Âµg/weekly of Pef interferon alpha-2a and 800 mg/daily
      of Ribavirin during 24 weeks or 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of patients with RNA-HCV undetectable 24 weeks</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of patients at the end of treatment</measure>
    <time_frame>48 weeks of treatmemt</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Co-Infection HIV-HCV</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg interferon + Ribavirin</intervention_name>
    <description>Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg interferon + Ribavirin</intervention_name>
    <description>Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients of 18-65 years of age

          -  Serologic evidence of chronic hepatitis C infection by detectable plasma HCV-RNA

          -  Serologic evidence of HIV-1 infection by ELISA and Western-blot

          -  Stable status of HIV-1 infection in the opinion of the investigator

          -  Negative urine or blood pregnancy test (for women of childbearing potential)
             documented within the 24-hour period prior to the first dose of study drug.
             Additionally, all fertile males and females must be using two forms of effective
             contraception during treatment and during the 6 months after treatment end. This may
             include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms,
             or implants, being surgically sterilized, or being in a post-menopausal state.

          -  Willingness to give written informed consent and willingness to participate to and
             comply with the study

        Exclusion Criteria:

          -  Women with ongoing pregnancy or breast feeding

          -  IFN or ribavirin therapy at any previous time

          -  Any investigational drug &lt;6 weeks prior to the first dose of study drug

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HCV

          -  Hepatocarcinoma observed

          -  History or other evidence of bleeding from esophageal varices or other conditions
             consistent with decompensated liver disease

          -  Active HIV-related opportunistic infection and/or malignancy requiring acute systemic
             therapy

          -  Absolute neutrophil count &lt;1500 cells/mm3

          -  Hgb &lt;12 g/dL in women or 13 g/dL in men or any patient for whom anemia would be
             medically problematic

          -  Hemoglobinopathy (e.g. thalassemia) or any other cause of or tendency for hemolysis

          -  Platelet count &lt;90000 cells/mm3

          -  Serum creatinine level &gt;1.5 times the upper limit of normal at screening

          -  History of severe psychiatric disease, especially depression. Severe psychiatric
             disease is defined as treatment with an antidepressant medication or a major
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for
             at least 3 months at any previous time or any history of the following: a suicidal
             attempt, hospitalization for psychiatric disease, or a period of disability due to a
             psychiatric disease

          -  History of a severe seizure disorder or current anticonvulsant use

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia,
             scleroderma, severe psoriasis, rheumatoid arthritis)

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation

          -  History of significant cardiac disease that could be worsened by acute anemia

          -  History of thyroid disease poorly controlled on prescribed medications. Patients with
             elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies
             to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded

          -  Evidence of severe retinopathy

          -  History of major organ transplantation with an existing functional graft

          -  History or other evidence of severe illness, malignancy or any other conditions which
             would make the patient, in the opinion of the investigator, unsuitable for the study

          -  History of any systemic anti-neoplastic or immunomodulatory treatment (including
             supraphysiologic doses of steroids and radiation) &lt;6 months prior to the first dose of
             study drug or the expectation that such treatment will be needed at any time during
             the study

          -  Drug use within 6 months of 1st dose and excessive alcohol consumption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Ortega, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>CÃ¡diz</state>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral-CÃ­es</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Gandia</name>
      <address>
        <city>Gandia</city>
        <state>Valencia</state>
        <zip>46700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de CastellÃ³n</name>
      <address>
        <city>CastellÃ³n</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Elena</name>
      <address>
        <city>Huelva</city>
        <zip>21004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>3003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>January 25, 2008</last_update_submitted>
  <last_update_submitted_qc>January 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Enrique Ortega</name_title>
    <organization>Hospital General Universitario of Valencia</organization>
  </responsible_party>
  <keyword>hepatitis</keyword>
  <keyword>co-infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

